Kyntra Bio Drops Prostate Cancer Drug After Years of Troubles
Kyntra Bio reports in its latest earnings that it is shutting down its mid-stage prostate cancer drug program because it failed to meet effectiveness goals. Formerly known as FibroGen, the company has faced a long string of setbacks, including previous trial failures and regulatory rejections, leaving it searching for new funding to survive.
According to Kyntra Bio's third-quarter 2026 earnings report, the company is terminating its phase 2 study of the CD46-targeting antibody-drug conjugate FG-3246 for metastatic castration-resistant prostate cancer, along with an accompanying PET imaging candidate. The decision comes after the therapy failed to meet the required efficacy threshold. This program was previously seen as a rare bright spot following years of corporate struggles.
Kyntra, formerly called FibroGen, has weathered major challenges, including a U.S. FDA rejection and trial failures for its lead anemia drug roxadustat, significant layoffs, and an SEC settlement over fraud allegations. To stay afloat, the company is now pinning its hopes on finding a strategic partner or raising external capital to fund a planned phase 3 trial for roxadustat in early 2027.
Financially, Kyntra expects the program cancellation to save over $20 million in operating expenses across two years. The company reported roughly $44 million in total holdings at the end of the third quarter, which it estimates will sustain operations through 2028, alongside quarterly revenue of $1.8 million.
View selection rationale
Importance 37/100
About this brief
- Content type
- News summary
- Source type
- Publisher report
- Original source
- Fierce Biotech ↗
- Source published
- Process
- AI-assisted discovery, translation, summarisation, classification and scoring; standards and corrections are maintained by the editorial desk.
- Verification
- The original URL and publication metadata are retained. This brief is not independently fact-checked unless explicitly stated.
- Published by
- Polyemergence Editorial Desk · PolyEmergence Pte Ltd.
- Conflict disclosure
- No financial or commercial conflict declared.